

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)

Interim Condensed Consolidated Financial Statements
For the three months period ended 31 March 2023

INDEX	PAGE
Independent auditor's review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of income	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 13

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY
(SAUDI JOINT STOCK COMPANY)**

Introduction:

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Sulaiman Al Habib Medical Services Group Company ("the Company") and its subsidiaries (collectively with the Company referred to as "the Group") as at 31 March 2023, and the related interim condensed consolidated statements of income, comprehensive income, changes in equity and cash flows for the three months period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review:

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" endorsed in the Kingdom of Saudi Arabia. A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion:

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services



Rashid S. Roshod
Certified Public Accountant
License No. (366)

Riyadh: 17 Shawwal 1444H
(7 May 2023)



Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of financial position
As at 31 March 2023

		31 March 2023	31 December 2022
		SR	SR
	Notes	(Unaudited)	(Audited)
Assets			
Current assets			
Cash and cash equivalents		3,263,672,511	2,746,989,005
Accounts receivable		846,390,415	741,713,503
Prepayments and other assets		158,252,548	181,380,520
Inventories		567,722,522	490,392,915
Total current assets		4,836,037,996	4,160,475,943
Non-current assets			
Investments in associates		180,351,399	186,999,110
Investments in equity instruments – Sukuk		300,000,000	300,000,000
Property and equipment	6	8,378,028,872	7,936,642,673
Total non-current assets		8,858,380,271	8,423,641,783
Total assets		13,694,418,267	12,584,117,726
Liabilities and equity			
Liabilities			
Current liabilities			
Current portion of long-term loans	9	157,874,831	167,651,299
Accounts payable		1,144,865,797	961,319,436
Accruals and other liabilities		1,376,937,099	1,247,476,180
Zakat payable		139,495,813	169,722,113
Current portion of lease liabilities		45,010,907	44,142,088
Total current liabilities		2,864,184,447	2,590,311,116
Non-current liabilities			
Long-term loans	9	3,657,137,663	3,032,584,836
Government grant		58,903,769	60,337,851
Lease liabilities		278,700,994	277,078,057
Employees' end-of-service benefits		538,455,516	518,141,099
Total non-current liabilities		4,533,197,942	3,888,141,843
Total liabilities		7,397,382,389	6,478,452,959
Equity			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Statutory reserve		876,157,331	876,157,331
Retained earnings		1,682,686,751	1,502,535,470
Equity attributable to equity holders of the parent		6,058,844,082	5,878,692,801
Non-controlling interests		238,191,796	226,971,966
Total equity		6,297,035,878	6,105,664,767
Total liabilities and equity		13,694,418,267	12,584,117,726



APPROVED BY:
FAISSAL AL NASSAR
CFO



APPROVED BY:
FAISSAL AL NASSAR
CEO (ACTING)



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of income
For the three months period ended 31 March 2023

	For the three months period ended	
	31 March 2023	31 March 2022
	SR	SR
Notes	(Unaudited)	(Unaudited)
Revenue	2,306,874,584	1,990,861,490
Cost of revenue	(1,523,233,091)	(1,332,299,916)
Gross profit	783,641,493	658,561,574
Selling and marketing expenses	(93,448,941)	(81,995,861)
General and administrative expenses	(179,624,189)	(154,478,381)
Operating income	510,568,363	422,087,332
Share of income of associates	3,867,383	1,825,792
Finance costs	(17,887,016)	(9,075,973)
Other income	34,312,052	21,824,933
Income before zakat	530,860,782	436,662,084
Zakat	(30,633,938)	(38,950,000)
Net income for the period	500,226,844	397,712,084
Net income for the period attributable to:		
Equity holders of the parent	489,266,545	390,504,743
Non-controlling interests	10,960,299	7,207,341
	500,226,844	397,712,084
Earnings per share:		
<i>Basic and diluted earnings per share attributable to equity holders of the parent</i>	1.40	1.12

10



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
FAISAL AL NASSAR
CEO (ACTING)



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of comprehensive income
For the three months period ended 31 March 2023

	For the three months period ended	
	31 March 2023	31 March 2022
	SR	SR
	(Unaudited)	(Unaudited)
Net income for the period	500,226,844	397,712,084
Other comprehensive income		
<i>Items that will not to be reclassified to profit or loss in subsequent periods:</i>		
Remeasurement gain on employees' end-of-service benefits	16,644,267	908,952
Other comprehensive Income for the period	16,644,267	908,952
Total comprehensive income for the period	516,871,111	398,621,036
Total comprehensive income for the period attributable to:		
Equity holders of the parent company	505,651,281	391,289,622
Non-controlling interests	11,219,830	7,331,414
	516,871,111	398,621,036



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
FAISAL AL NASSAR
CEO (ACTING)



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of changes in equity
For the three months period ended 31 March 2023

	Attributable to equity holders of the parent				Non-controlling interests	Total equity
	Issued and paid-up share capital	Statutory reserve	Retained earnings	Total	SR	SR
	SR	SR	SR	SR	SR	SR
As at 1 January 2023	3,500,000,000	876,157,331	1,502,535,470	5,878,692,801	226,971,966	6,105,664,767
Net income for the period	-	-	489,266,545	489,266,545	10,960,299	500,226,844
Other comprehensive income	-	-	16,384,736	16,384,736	259,531	16,644,267
Total comprehensive income	-	-	505,651,281	505,651,281	11,219,830	516,871,111
Dividends (note 8)	-	-	(325,500,000)	(325,500,000)	-	(325,500,000)
As at 31 March 2023 (Unaudited)	<u>3,500,000,000</u>	<u>876,157,331</u>	<u>1,682,686,751</u>	<u>6,058,844,082</u>	<u>238,191,796</u>	<u>6,297,035,878</u>
As at 1 January 2022	3,500,000,000	711,082,326	1,128,089,112	5,339,171,438	187,904,565	5,527,076,003
Net income for the period	-	-	390,504,743	390,504,743	7,207,341	397,712,084
Other comprehensive income	-	-	784,879	784,879	124,073	908,952
Total comprehensive income	-	-	391,289,622	391,289,622	7,331,414	398,621,036
Dividends (note 8)	-	-	(245,000,000)	(245,000,000)	-	(245,000,000)
As at 31 March 2022 (Unaudited)	<u>3,500,000,000</u>	<u>711,082,326</u>	<u>1,274,378,734</u>	<u>5,485,461,060</u>	<u>195,235,979</u>	<u>5,680,697,039</u>



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
FAISAL AL NASSAR
CEO (ACTING)



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of cash flows
For the three months period ended 31 March 2023


	2023 SR (Unaudited)	2022 SR (Unaudited)
Operating activities		
Income before zakat	530,860,782	436,662,084
Non-cash adjustments to reconcile income before zakat to net cash flows:		
Depreciation	77,920,776	76,602,968
Share of income of associates	(3,867,383)	(1,825,792)
Allowance for expected credit losses	52,022,019	54,049,053
Finance costs	17,887,016	9,075,973
Employees' end-of-service benefits	46,120,854	30,578,936
	720,944,064	605,143,222
Working capital adjustments:		
Accounts receivable	(156,698,931)	(48,696,081)
Inventories	(77,329,607)	(43,129,357)
Prepayments and other assets	24,267,906	4,321,793
Accounts payable	183,546,361	97,063,714
Accruals and other liabilities	124,389,447	125,147,206
Cash generated from operations	819,119,240	739,850,497
Zakat paid	(60,860,238)	(69,362,897)
Employees' end-of-service benefits paid	(9,162,170)	(9,962,981)
Net cash from operating activities	749,096,832	660,524,619
Investing activities		
Purchase of property and equipment	(510,807,510)	(310,723,228)
Dividends from associates	10,515,094	-
Investments in equity instruments – Sukuk	-	(150,000,000)
Net cash used in investing activities	(500,292,416)	(460,723,228)
Financing activities		
Proceeds from long-term loans, net	613,387,826	494,429,486
Lease liabilities paid	(7,147,642)	(11,026,645)
Finance costs paid	(12,861,094)	(9,992,737)
Dividends paid	(325,500,000)	-
Net cash from financing activities	267,879,090	473,410,104
Net increase in cash and cash equivalents	516,683,506	673,211,495
Cash and cash equivalents at the beginning of the period	2,746,989,005	2,643,829,664
Cash and cash equivalents at the end of the period	3,263,672,511	3,317,041,159
Non-cash transactions:		
Recognition of right-of-use assets	9,639,399	6,489,207
Recognition of lease liabilities	9,639,399	6,489,207
Dividends payables	-	245,000,000



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
FAISAL AL NASSAR
CEO (ACTING)



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

1. Corporate information and activities

Dr. Sulaiman Al Habib Medical Services Group Company (the "Company") (a Saudi Listed Joint Stock Company) is registered in Riyadh, under commercial registration number 1010118330 dated 11 Jumada al-thani 1414H (corresponding to 25 November 1993). The registered office is located at Olaya District, P.O. Box 301578, Riyadh 11372, Kingdom of Saudi Arabia (the "Kingdom"), and the Company was listed on the Saudi Stock Exchange (Tadawul) on 22 Rajab 1441H (corresponding to 17 March 2020).

The activities of the Company and its subsidiaries (collectively referred to as "the Group") are to provide private health services and ancillary services for its operations in the Kingdom and the region through the establishment, management, and operation of hospitals, general and specialized medical complexes, day surgery centers, pharmaceutical facilities, and other ancillary areas which include providing services of Home health care, specialized medical laboratories, technology services & information systems, providing facility maintenance services, Tele-medicine services, revenue cycle management services, medical equipment maintenance services, and real estate activity.

The Company has two branches, the first branch is located in Riyadh, Kingdom, "Branch of Dr. Sulaiman Al Habib Medical Services Group Company" ("the Branch") under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The Branch is engaged in wholesale and retail trade in cosmetics and maintenance of medical devices and equipment. The second one is located in the Kingdom of Bahrain, "Dr. Sulaiman Al-Habib Medical Services Group Holding Company - Foreign Branch" ("the Foreign Branch") under commercial registration number 81609-1 dated 22 Rajab 1433H (corresponding to 12 June 2012). The Foreign Branch is engaged in activities of head offices and management offices.

The number of shares is 350,000,000 and the share value is 10 Saudi riyals.

The interim condensed consolidated financial statements include the financial information of the branches mentioned above and subsidiaries mentioned in note 3.

2. Basis of preparation

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by Saudi Organization for Chartered and Professional Accountants (collectively referred to as "IFRS" as endorsed in Kingdom of Saudi Arabia").

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2022.

An interim period is considered an integral part of the whole fiscal year, however, the results of operations for the interim periods may not be a fair indication of the results of the full year operations.

These interim condensed consolidated financial statements are prepared on a historical cost basis. The interim condensed consolidated financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Company and all values are rounded to the nearest one Riyal, except when otherwise indicated.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2023

3. Basis of consolidation

These interim condensed consolidated financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as “the Group”), mainly domiciled in Kingdom of Saudi Arabia (“KSA”) and United Arab Emirates (“UAE”) as at 31 March 2023 & 31 December 2022:

	Country of incorporation and business	Activities	Ownership %	
			31 March 2023	31 December 2022
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare services	100%	100%
Al Gharb Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarot Diagnostic Medical Company	KSA	Laboratory Services	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahaba for IT & Communication Company	KSA	IT Support Services	100%	100%
Rawabet Medical Company*	KSA	Medical Services	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiyah Hospital for Healthcare Company	KSA	Hospital	100%	100%
Taswyat Administrative Company	KSA	Revenue cycle management	100%	100%
Al Marakez Al Awwalyah for Health Care Company	KSA	Medical Primary Healthcare centers	100%	100%
Wrass Real Estate Company	KSA	Real Estate	100%	100%
Flow Medical Company	KSA	Medical equipments maintenance	100%	100%
Sehat Al Kharj for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Gharb for Health Care Company	KSA	Hospital	100%	100%
Bawabat Al Shamal for Health Care Company	KSA	Hospital	100%	100%
Sehat Al Hamra for Health Care Company**	KSA	Hospital	100%	-

* During the period, the company name changed from “Intensive Care Company for Healthcare”.

** During the period, the Group established new subsidiary “Sehat Al Hamra for Health Care Company”.

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns.

3. Basis of consolidation (continued)

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

4. Summary of significant accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2022.

5. Segment Information

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM").

The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2023

5. Segment Information (continued)

The identified key segments are Hospitals/Healthcare Facilities, Pharmacies and HMG Solutions/Others (which includes IT support services, laboratory services, home healthcare services, medical equipments maintenance, revenue cycle management and real estate). The segment results for the period ended 31 March 2023 and the reconciliation of the segment measures to the respective statutory items included in the interim condensed consolidated financial statements are as follows:

For the three months period ended 31 March 2023 (Unaudited)	Hospitals/ Healthcare Facilities	Pharmacies	HMG Solutions / Others	Total
	<i>SR' millions</i>			
Saudi Arabia:				
Revenue	1,636	465	62	2,163
Gross profit	593	152	14	759
Outside Saudi Arabia:				
Revenue	117	26	1	144
Gross profit	18	6	1	25
Total				
Revenue	1,753	491	63	2,307
Gross profit	611	158	15	784
Unallocated income (expenses)				
Selling and marketing				(93)
General and administrative				(180)
Operating income				511
Share of income of associates				4
Finance costs				(18)
Other income				34
Income before zakat				531
Zakat				(31)
Net income for the period				500
As at 31 March 2023 (Unaudited)				
Saudi Arabia:				
Total assets	9,726	443	2,959	13,128
Total liabilities	5,898	628	734	7,260
Outside Saudi Arabia				
Total assets	506	54	6	566
Total liabilities	114	20	3	137
Total				
Total assets	10,232	497	2,965	13,694
Total liabilities	6,012	648	737	7,397

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2023

5. Segment Information (continued)

For the three months period ended 31 March 2022 (Unaudited)	Hospitals/ Healthcare Facilities	Pharmacies	HMG Solutions / Others	Total
	SR' millions			
Saudi Arabia:				
Revenue	1,400	398	67	1,865
Gross profit	476	135	28	639
Outside Saudi Arabia:				
Revenue	106	19	1	126
Gross profit	15	4	1	20
Total				
Revenue	1,506	417	68	1,991
Gross profit	491	139	29	659
Unallocated income (expenses)				
Selling and marketing				(82)
General and administrative				(155)
Operating income				422
Share of income of associates				2
Finance costs				(9)
Other income				22
Income before zakat				437
Zakat				(39)
Net income for the period				398
As at 31 December 2022 (audited)				
Saudi Arabia:				
Total assets	8,495	378	3,151	12,024
Total liabilities	5,080	540	723	6,343
Outside Saudi Arabia				
Total assets	508	42	10	560
Total liabilities	114	18	3	135
Total				
Total assets	9,003	420	3,161	12,584
Total liabilities	5,194	558	726	6,478

6. Property and equipment

	As at 31 March 2023 SR (Unaudited)	As at 31 December 2022 SR (Audited)
Property and equipment	8,056,202,778	7,610,726,965
Right-of-use assets	321,826,094	325,915,708
	8,378,028,872	7,936,642,673

7. Zakat

The Company has filed its consolidated zakat returns for the Company and its subsidiaries (100% owned subsidiaries as per note 3) to ZATCA and obtained zakat certificates for all previous years up to 31 December 2022 and final Zakat assessments up to 31 December 2020.

As for other subsidiaries (with ownership less than 100% as per note 3) that are not part of the consolidated zakat base, which required submitting separate zakat returns. Sehat Al Sharq Medical Limited Company, Gharb Jeddah Hospital Company, and Al Wosta Medical Limited Company submitted their zakat returns to ZATCA, and zakat certificates were obtained up to 31 December 2022. Sehat Al Sharq Medical Limited Company obtained the final zakat assessments for all years up to 31 December 2016. Gharb Jeddah Hospital Company obtained the final zakat assessments for all years up to 31 December 2020.

8. Dividends

The Board of Directors, in their meetings on 18 February 2023 resolved to distribute interim dividends of SR 0.93 per share totaling to SR 325,500,000 (2022: SR 0.70 per share totalling to SR 245,000,000). This will be endorsed by the Company's upcoming general assembly.

9. Long-term loans

	As at 31 March 2023 SR (Unaudited)	As at 31 December 2022 SR (Audited)
Current-portion of loans:		
Loans from local banks (i)	123,671,425	123,671,425
Loans from Ministry of Finance (ii)	34,203,406	43,979,874
	157,874,831	167,651,299
Non-current portion of loans:		
Loans from local banks (i)	3,311,864,265	2,688,699,978
Loans from Ministry of Finance (ii)	345,273,398	343,884,858
	3,657,137,663	3,032,584,836

- i) Loans from local banks
The Group is financed through Islamic facilities in the form of long-term and short-term loans (Murabaha / Tawarruq) from local banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin. The facilities are secured by corporate promissory notes.
- ii) Loans from Ministry of Finance (MoF)
The Group's long-term financing includes MoF non-interest bearing loans to finance the capital expenditures related to the Company and its subsidiaries. The loan repayment instalments are settled on equal yearly installments. Certain assets are pledged against the loans obtained from the MoF.

10. Earnings per share

Basic and diluted earnings per share ("EPS") is calculated by dividing the income for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the income for the period attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

	For the three months period ended	
	31 March 2023 SR (Unaudited)	31 March 2022 SR (Unaudited)
Net income for the period attributable to equity holders of the parent	489,266,545	390,504,743
Weighted average number of ordinary shares	350,000,000	350,000,000
Basic and diluted earnings per share attributable to equity holders of the parent	1.40	1.12

11. Fair values

Financial instruments comprise financial assets and financial liabilities. Financial assets consist of cash and cash equivalents and accounts receivable. Financial liabilities consist of long-term loans, accounts payable, amounts due to related parties, accruals and other liabilities and zakat payable.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date largely.

12. Subsequent events

In the opinion of management, no significant events have occurred subsequent to 31 March 2023 that would have a material impact on financial position or financial performance of the Group.

13. Approval of the interim condensed consolidated financial statements

These interim condensed consolidated financial statements were approved for issuance by the Board of Directors on 16 Shawwal 1444H (corresponding to 06 May 2023).